drugset / Trial / NCT04153188

Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea

NCT04153188

Phase 4 Completed 34 enrolled Candela Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will compare treatment outcome with pulsed dye laser, when used used as an adjunctive treatment to oxymetazoline HCl 1% cream, compared to oxymetazoline HCL 1% cream alone, for patients with moderate or severe erythematotelangiectatic rosacea.

Timeline

Start
2019-01-15
Primary completion
2020-11-13
Completion
2021-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymetazoline Other / unclassified 1 % Topical

Indications